| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 9,651 | 7,300 | 6,829 | 8,507 |
| Cost of goods sold | 1,569 | 1,610 | 1,596 | 1,519 |
| Gross profit | 8,082 | 5,690 | 5,233 | 6,988 |
| Research and development | 3,857 | 3,335 | 5,316 | 6,269 |
| Sales and marketing | 3,428 | 3,504 | 3,936 | 5,786 |
| General and administrative | 5,966 | 5,482 | 6,028 | 8,080 |
| Restructuring expense | NaN | 2,666* | 3,058 | NaN |
| Goodwill impairment | NaN | 889* | NaN | NaN |
| Depreciation and amortization | 1,016 | 1,041 | 1,044 | 1,080 |
| Total operating expenses | 14,267 | 16,916 | 19,382 | 21,215 |
| Operating loss | -6,185 | -11,226 | -14,149 | -14,227 |
| Interest income | 1,435 | 1,630 | 1,733 | 1,870 |
| Total other income | 1,435 | 1,630 | 1,733 | 1,870 |
| Loss before income taxes | -4,750 | -9,596 | -12,416 | -12,357 |
| Net loss | -4,750 | -9,596 | -12,416 | -12,357 |
| Basic EPS | -0.04 | -0.09 | -0.12 | -0.12 |
| Diluted EPS | -0.04 | -0.09 | -0.12 | -0.12 |
| Basic Average Shares | 106,875,087 | 106,744,321 | 106,613,075 | 106,403,540 |
| Diluted Average Shares | 106,875,087 | 106,744,321 | 106,613,075 | 106,403,540 |
MAXCYTE, INC. (MXCT)
MAXCYTE, INC. (MXCT)